Investment
Features
FeesSafety
Academy
More
Pluang+

Insight Enterprises' price target raised to $180 after strong Q2 earnings and revenue growth.

Analyst Insights
10 Aug 2026
Alex Lavoie
View Source
Bullish
pluang ai news

Insight Enterprises reported impressive Q2 results with earnings per share of $3.86, beating estimates by nearly 31%, and revenue of $2.40 billion, up 15% year-over-year. Gross profit increased by 18%, prompting the company to raise its full-year financial outlook and unveil a new three-year strategic plan focused on AI infrastructure and digital transformation. Analyst Vincent Colicchio raised the price target from $120 to $180, indicating a 17% potential upside, reflecting strong investor confidence in the company's growth and profitability prospects.

More News

Tesla posts record deliveries but misses earnings amid AI investments; analyst upgrades stock to Buy.

Tesla posts record deliveries but misses earnings amid AI investments; analyst upgrades stock to Buy.

Tesla delivered a record 480,126 vehicles and generated $28.24 billion in revenue but missed earnings expectations with a non-GAAP EPS of $0.33, 38.51% below forecasts. The company faced financial pressures including a negative free cash flow of $1.0...

Market News
Neutral
1 hour ago
Caledonia Mining beats Q2 earnings estimates with $1.36 EPS, driven by higher gold production and prices.

Caledonia Mining beats Q2 earnings estimates with $1.36 EPS, driven by higher gold production and prices.

Caledonia Mining Corporation Plc reported a strong Q2 2026 earnings per share of $1.36, far exceeding analyst estimates of $0.54. This was driven by an 18% increase in gold production at its Blanket Mine and a 34% rise in the realized gold price, boo...

Company Fundamentals
Bullish
1 hour ago
Analyst raises iRhythm price target to $168 after strong Q2 earnings beat expectations.

Analyst raises iRhythm price target to $168 after strong Q2 earnings beat expectations.

iRhythm Technologies reported strong Q2 results with revenue up 20.1% to $224.2 million and earnings of $0.58 per share, beating expectations. Profitability improved with a gross margin of 72.8% and adjusted EBITDA of $43.3 million. Following this, T...

Analyst Insights
Bullish
2 hours ago
Heron Therapeutics misses Q2 earnings and revenue estimates, pauses sales expansion, withdraws full-year outlook.

Heron Therapeutics misses Q2 earnings and revenue estimates, pauses sales expansion, withdraws full-year outlook.

Heron Therapeutics reported a Q2 loss per share of -$0.03, missing analyst expectations of -$0.02, with revenue of $37.67 million falling short of the $42.19 million estimate. Despite 44% growth in its acute-care franchise, slower expansion of key pr...

Company Fundamentals
Bearish
2 hours ago
Teleflex reports Q2 revenue growth and $2B divestitures, plans debt cut and share buybacks

Teleflex reports Q2 revenue growth and $2B divestitures, plans debt cut and share buybacks

Teleflex reported Q2 revenue of $570.3 million, driven by its Vascular and Surgical segments, with adjusted EPS up 1.7% to $1.76. The company is selling its Acute Care, Interventional Urology, and OEM businesses for about $2.03 billion in cash to red...

Company Fundamentals
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App